

OMB APPROVAL	
OMB Number:	3235-0287
Expires:	December 31, 2014
Estimated average burden hours per response	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* PATOU GARY (Last) (First) (Middle) C/O MPM ASSET MANAGEMENT, 601 GATEWAY BLVD., SUITE 350 (Street) SOUTH SAN FRANCISCO CA 94080 (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol Pacira Pharmaceuticals, Inc. [PCRX]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner <input checked="" type="checkbox"/> Officer (give title below) Other (specify below) Chief Medical Officer
	3. Date of Earliest Transaction (Month/Day/Year) 07/14/2014	
	4. If Amendment, Date of Original Filed (Month/Day/Year)	

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned										
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	07/14/2014		M ⁽¹⁾		2,460	A	\$ 1.61	2,460	D	
Common Stock	07/14/2014		M ⁽¹⁾		20,237	A	\$ 5.49	22,697	D	
Common Stock	07/14/2014		M ⁽¹⁾		7,303	A	\$ 10.81	30,000	D	
Common Stock	07/14/2014		S ⁽¹⁾		27,593	D	\$ 86.91 ⁽²⁾	2,407	D	
Common Stock	07/14/2014		S ⁽¹⁾		2,107	D	\$ 87.58 ⁽³⁾	0	D	
Common Stock								702	I	See Footnote ⁽⁴⁾

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	V	(A)	(D)	Date Exercisable	Expiration Date						Title
Stock Option (Right to Buy)	\$ 1.61	07/14/2014		M ⁽¹⁾			2,460	(5)	09/02/2020	Common Stock	2,460	\$ 0	2,460	D	
Stock Option (Right to Buy)	\$ 5.49	07/14/2014		M ⁽¹⁾			20,237	(6)	12/29/2020	Common Stock	20,237	\$ 0	5,296	D	
Stock Option (Right to Buy)	\$ 10.81	07/14/2014		M ⁽¹⁾			7,303	(7)	06/05/2022	Common Stock	7,303	\$ 0	32,697	D	

Explanation of Responses:

1. This transaction was pursuant to a 10b5-1 Plan dated March 11, 2014.
2. Represents weighted average sales price. The shares were sold at prices ranging from \$86.50 to \$87.49. The Reporting Person will provide upon request, to the SEC, the Issuer or any securityholder of the Issuer, full information regarding the number of shares sold at each separate price.
3. Represents weighted average sales price. The shares were sold at prices ranging from \$87.52 to \$87.64. The Reporting Person will provide upon request, to the SEC, the Issuer or any securityholder of the Issuer, full information regarding the number of shares sold at each separate price.
4. Shares held by Patou Family Trust, of which the reporting person is trustee.
5. 25% of the option shares vested on September 2, 2011 and the remaining 75% of the option shares vest monthly over the next 36 months. The option shares become exercisable when vested.
6. 25% of the option shares vested on December 29, 2011 and the remaining 75% of the option shares vest monthly over the next 36 months. The option shares become exercisable when vested.
7. 25% of the option shares vested on June 5, 2013 and the remaining 75% of the option shares vest monthly over the next 36 months. The option shares become exercisable when vested.

/s/ Gary Patou

07/15/2014

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.